Literature DB >> 3477545

Induction of monocytic differentiation of HL-60 cells by 1,25-dihydroxyvitamin D analogs.

V K Ostrem1, W F Lau, S H Lee, K Perlman, J Prahl, H K Schnoes, H F DeLuca.   

Abstract

1,25-Dihydroxyvitamin D3, the hormonal form of vitamin D, induces differentiation of HL-60 human promyelocytes into monocyte-like cells in vitro. We assessed the relative activity of 30 analogs of 1,25-dihydroxyvitamin D3 in inducing development of monocytic markers in HL-60 cells. The three differentiation markers assayed were nonspecific acid esterase activity, nitro blue tetrazolium reducing activity, and phagocytic capacity. Of the known metabolites of vitamin D, 1,25-dihydroxyvitamin D3 is the most active; 50% of the cells exhibit the mature phenotype following a 4-day treatment with 10(-8) M 1,25-dihydroxyvitamin D3. Removal of either the C-1 or C-25-hydroxyl group reduces activity by 2 orders of magnitude, while epimerization of the 1 alpha- to 1 beta-hydroxyl group virtually abolishes activity. Elongation of the steroidal side chain of 1,25-dihydroxyvitamin D3 by addition of one carbon at C-24 or C-26 improves the potency by an order of magnitude. Truncation of the steroidal side chain leads to a 10-fold reduction in activity for each carbon removed. Elimination of the C-26 and C-27 methyl groups reduces activity 100-fold. Analogs with short aliphatic side chains as 1 alpha-hydroxyhomo- and bishomopregnacholecalciferol have surprisingly high activity, being only 20-fold less potent than the natural hormone. The activity of most analogs in the HL-60 system parallels their known relative affinities for the well characterized 1,25-dihydroxyvitamin D3 receptor in chick intestine, providing further evidence that this function of 1,25-dihydroxyvitamin D3 is receptor mediated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3477545

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia.

Authors:  Thomas H Shin; Christopher Brynczka; Farshid Dayyani; Miguel N Rivera; David A Sweetser
Journal:  Leuk Res       Date:  2016-07-21       Impact factor: 3.156

2.  Effect of 24R,25-dihydroxyvitamin D3 on the formation and function of osteoclastic cells.

Authors:  H Yamato; R Okazaki; T Ishii; E Ogata; T Sato; M Kumegawa; K Akaogi; N Taniguchi; T Matsumoto
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

Review 3.  Ring-A-seco analogs of 1α,25-dihydroxy-19-norvitamin D3.

Authors:  Agnieszka Glebocka; Rafal R Sicinski; Lori A Plum; Hector F Deluca
Journal:  J Steroid Biochem Mol Biol       Date:  2012-10-09       Impact factor: 4.292

4.  Calcium regulating activity of 24a-homo-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3 and 26,27-dimethyl-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3.

Authors:  M Harada; T Miyahara; M Miyata; H Komiyama; A Sugure; Y Ikemoto; S Kondo; T Takamura; S Higuchi; S Otomo
Journal:  Calcif Tissue Int       Date:  1993-11       Impact factor: 4.333

5.  Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics.

Authors:  Matthias Farlik; Nathan C Sheffield; Angelo Nuzzo; Paul Datlinger; Andreas Schönegger; Johanna Klughammer; Christoph Bock
Journal:  Cell Rep       Date:  2015-02-26       Impact factor: 9.423

6.  A theoretical insight to understand the molecular mechanism of dual target ligand CTA-018 in the chronic kidney disease pathogenesis.

Authors:  Selvaraman Nagamani; Karthikeyan Muthusamy
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

7.  Synthesis of C2-Alkoxy-Substituted 19-Nor Vitamin D3 Derivatives: Stereoselectivity and Biological Activity.

Authors:  Yuka Mizumoto; Ryota Sakamoto; Akiko Nagata; Suzuka Sakane; Atsushi Kittaka; Minami Odagi; Masayuki Tera; Kazuo Nagasawa
Journal:  Biomolecules       Date:  2022-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.